Organon (OGN) Cash from Operations (2020 - 2026)
Organon (OGN) posted quarterly Cash from Operations of 107000000.0 for Q2 2026, down 51.36% year-over-year from 220000000.0 in Q2 2025, and down 52.44% on a QoQ basis from 225000000.0 in Q1 2026.
Organon (OGN) Cash from Operations (2020 - 2026) Analysis & Trends
Organon has reported Cash from Operations for 7 years, with the latest figure at 107000000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 107000000.0, down 51.36% year-over-year; the trailing twelve-month figure through Jun 2026 was 737000000.0 (down 10.77% YoY), and the FY2025 annual result was 700000000.0, down 25.45% from the prior year.
- Cash from Operations fell to 107000000.0 in Q2 2026, from 225000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 397000000.0 in Q4 2023 and troughed at 27000000.0 in Q2 2023.
- A 5-year average of 201555555.56 and a median of 185500000.0 in 2022 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2022, when Cash from Operations sank 90.54%; it then soared 1129.63% in 2024.
- A 5-year view of Cash from Operations shows it stood at 267000000.0 in 2022, then jumped by 48.69% to 397000000.0 in 2023, then declined by 1.76% to 390000000.0 in 2024, then slumped by 63.85% to 141000000.0 in 2025, then retreated by 24.11% to 107000000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 107000000.0 in Q2 2026, 225000000.0 in Q1 2026, and 141000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 107.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107.00 Mn |
| Jun 30, 2026 | 107.00 Mn |
| Mar 31, 2026 | 225.00 Mn |
| Mar 31, 2026 | 225.00 Mn |
| Dec 31, 2025 | 141.00 Mn |
| Dec 31, 2025 | 141.00 Mn |
| Sep 30, 2025 | 264.00 Mn |
| Sep 30, 2025 | 264.00 Mn |
| Jun 30, 2025 | 220.00 Mn |
| Jun 30, 2025 | 220.00 Mn |
| Mar 31, 2025 | 75.00 Mn |
| Mar 31, 2025 | 75.00 Mn |
| Dec 31, 2024 | 390.00 Mn |
| Dec 31, 2024 | 390.00 Mn |
| Sep 30, 2024 | 141.00 Mn |
| Sep 30, 2024 | 141.00 Mn |
| Jun 30, 2024 | 332.00 Mn |
| Jun 30, 2024 | 332.00 Mn |
| Mar 31, 2024 | 76.00 Mn |
| Mar 31, 2024 | 76.00 Mn |